TAPUR - Calfa, Carmen
-
Investigator:
Carmen Calfa
Email
Coordinator: Dina Caceres
+1 (305) 2437561
IRB: 20170529
SDG: Breast Cancer
Disease Site(s): Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
Sponsor: ASCO
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"
20200056 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator:
IRB: 20200056
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
Sponsor: DECIPHERA
Enrolling Sites:
Sylvester
Title: A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"
20210890 - Merchan Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator:
IRB: 20210890
SDG: Colorectal Cancer
Disease Site(s): Multiple
Sponsor: Exelixis Pharmaceuticals
Enrolling Sites:
Deerfield
Gables
Plantation
SylvesterTitle: A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Eligibility Criteria - NCT03845166 *This information has been extracted from " www.clinicaltrials.gov"
20220871 - MINOCHA VINAY
-
Investigator:
VINAY MINOCHA
Email
Coordinator:
IRB: 20220871
SDG: Colorectal Cancer
Disease Site(s): Colon
Sponsor: PFIZER
Enrolling Sites:
Plantation
SylvesterTitle: A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI-H/DMMR METASTATIC COLORECTAL CANCER
Eligibility Criteria - NCT05217446 *This information has been extracted from " www.clinicaltrials.gov"
20210855 - Pimentel Agustin
-
Investigator:
Agustin Pimentel
Email
Coordinator: Siudy Vasquez Escobar
+1 (305) 2432122 x62122
IRB: 20210855
SDG: Colorectal Cancer
Disease Site(s): Multiple
Sponsor: PFIZER
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC
Eligibility Criteria - NCT04607421 *This information has been extracted from " www.clinicaltrials.gov"
20220773 - Pimentel Agustin
-
Investigator:
Agustin Pimentel
Email
Coordinator:
IRB: 20220773
SDG: Colorectal Cancer
Disease Site(s): Colon,Rectum
Sponsor: Bexion Pharmaceuticals
Enrolling Sites:
Sylvester
Title: A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma
Eligibility Criteria - NCT05322590 *This information has been extracted from " www.clinicaltrials.gov"
20220823 - Pimentel Agustin
-
Investigator:
Agustin Pimentel
Email
Coordinator:
IRB: 20220823
SDG: Colorectal Cancer
Disease Site(s): Multiple
Sponsor: Gritstone Bio, Inc.
Enrolling Sites:
Deerfield
Gables
Plantation
SylvesterTitle: A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer
Eligibility Criteria - NCT05141721 *This information has been extracted from " www.clinicaltrials.gov"
DECREASE - Portelance, Lorraine
-
Investigator:
Lorraine Portelance
Email
Coordinator:
IRB: 20191276
SDG: Colorectal Cancer
Disease Site(s): Anus
Sponsor: ECOG
Enrolling Sites:
Aventura
Deerfield
Gables
Plantation
SylvesterTitle: A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Eligibility Criteria - NCT04166318 *This information has been extracted from " www.clinicaltrials.gov"
20210172 - Portelance Lorraine
-
Investigator:
Lorraine Portelance
Email
Coordinator: Samantha St. Armand
+1 (305) 2432006
IRB: 20210172
SDG: Colorectal Cancer
Disease Site(s): Rectum
Sponsor: SCCC
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: Selective Treatment with Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy Combined with Total Neoadjuvant ChemoTherapy for the Conservative Management of Locally Advanced Rectal Cancer
Eligibility Criteria - NCT05412082 *This information has been extracted from " www.clinicaltrials.gov"
AMC-095 - Ramos, Juan Carlos
-
Investigator:
Juan Carlos Ramos
Email
Coordinator:
IRB: 20160656
SDG: Lymphoma
Disease Site(s): Anus,Lip, Oral Cavity and Pharynx,Lung,Other Hematopoietic
Sponsor: AMC
Enrolling Sites:
Sylvester
Title: A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"
RPL-001-16 - Rodriguez, Estelamari
-
Investigator:
Estelamari Rodriguez
Email
Coordinator: Yanel Diaz Caro
+1 (786) 5828551
IRB: 20180802
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bladder,Breast-Female,Colon,Melanoma, skin,Other Skin
Sponsor: REPLIMUNE
Enrolling Sites:
Sylvester
Title: RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"
ATRC-101-A01 - Valdes, Frances
-
Investigator:
Frances Valdes
Email
Coordinator: Yanel Diaz Caro
+1 (786) 5828551
IRB: 20200938
SDG: Breast Cancer
Disease Site(s): Breast,Colon,Lung,Melanoma, skin,Ovary
Sponsor: Atreca Inc
Enrolling Sites:
Sylvester
Title: A Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination with Other Anticancer Agents in Adults with Advanced Solid Malignancies
Eligibility Criteria - NCT04244552 *This information has been extracted from " www.clinicaltrials.gov"